ArticleEJNMMI radiopharmacy and chemistry2023
Improved quality control of [
Article in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 8 citations in OpenAlex.
- Real-world outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- Inline gamma spectroscopy and liquid scintillation HPLC reveal daughters inEJNMMI radiopharmacy and chemistry · 2026Article
- Development and evaluation of improved in-house procedure for radiolabelling of theranostic agent [EJNMMI radiopharmacy and chemistry · 2026Article
- GMP-compliant automated synthesis and quality control of [EJNMMI radiopharmacy and chemistry · 2026Article
- A scalable protocol for the radiosynthesis of clinical grade lutetium-177-labeled theranostic agents.Nature protocols · 2026Article
- Assessment of quality control and effect of radiolysis on the in vivo biodistribution of [EJNMMI radiopharmacy and chemistry · 2025Article
- Optimization of the radiosynthesis of the PSMA-targeting drugs [EJNMMI radiopharmacy and chemistry · 2025Article
- Tailored Reaction Conditions and Automated Radiolabeling of [International journal of molecular sciences · 2025Article
- Multifactorial analysis of radiochemical purity in high-activityEJNMMI radiopharmacy and chemistry · 2025Article
- Ac-225 radiochemistry through the lens of [EJNMMI radiopharmacy and chemistry · 2025Article
- Role of Radioiodine in Cancer Therapy: A Review of the Design and Challenges in Selecting Radioligands from Natural Sources.Drug design, development and therapy · 2025Review
- Efficacy and safety of rechallenge with [European journal of nuclear medicine and molecular imaging · 2024Article
- Quality Assurance Investigations and Impurity Characterization during Upscaling of [Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTargeted radionuclide therapy with [
resultsThe described HPLC method met the defined acceptance criteria in terms of accuracy, specificity, robustness, linearity, range and LOQ. HPLC analysis revealed symmetrical peaks and quantitative recovery from the column. Batch data showed a radiochemical purity > 95% as determined by HPLC, stability data a pronounced degradation due to radiolysis, which could be limited by addition of ascorbic acid, dilution and storage at low temperatures. The main radiochemical impurity was found to be the de-iodinated form of [
conclusionOverall the described combination of HPLC and TLC provides a reliable tool for quality control of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.